



VRL/SEC/BSE/91

July 9<sup>th</sup>, 2012

Dept. of Corporate Services  
The Stock Exchange, Mumbai  
25<sup>th</sup> Floor, Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai

Sub. : Venus Remedies introduces "Ready-to-Use" Single Vial Taxedol in India

Dear Sir/Madam,

This is to inform you that Venus Remedies Limited has introduced for the first time a nanotechnology based "Ready-to-Use" Single Vial Docetaxel in the domestic market under the brand name "TAXEDOL".

TAXEDOL is ready to use single vial formulation available in three strengths 20mg/0.5 ml, 80mg/2 ml and 120mg/3ml. This one-vial formulation is having the advantage of requiring a single dilution step in suitable infusion solutions prior to administration. Thus, offering cost-effective solution to patients. Moreover, research at Venus Medicine Research Center has established that this novel technology is unique and will offer significant therapeutic advantage over all available similar and competing products.

TAXEDOL (Docetaxel) is a single unit stable, pharmaceutical formulation which has lesser impurities in comparison to innovator product. This one vial formulation of Docetaxel will not only make the administration of the drug easier by introducing the premix solution but at the same time will provide enhanced safety to patients and para-medical staff. Furthermore, the nano-scale size of the formulation results in improved penetration, higher efficacy, improved safety and lesser side effects.

The formulation comprises of Docetaxel in nano particle form which gives 11% higher cancer cell killing potential as compared to existing Docetaxel. The Company has received very positive response from the medical fraternity especially for the 120mg strength as it is convenient not only for the medical staff but also for the patient.

A semi-synthetic cytostatic taxane analogue, Docetaxel is considered as one of the most effective and successful oncology products, which is used mainly for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, head and neck cancer and ovarian cancer.

TAXEDOL, a "Ready-to-Use" single vial will not only weed out the competition from other players in the market but is hopeful of capturing significant share in Rs 1, 500 crore Indian Cancer Drug Industry, which is speculated to show a steady growth over the coming few years.

Besides this, we are successfully marketing Docetaxel under the brand name "DOXOL" in the various emerging markets of Africa, Asia, CIS and LAC. Recently, the grant of European Market Authorization for Portugal for Docetaxel has further opened up new grounds for Venus Remedies to cater to the EU market. The company is also contributing successfully in the oncology segment for Europe and ROW through its wide array of key products, which includes Bortezomib, Pemetrexed, Paclitaxel, Gemcitabine to name a few.

Yours faithfully,  
for VENUS REMEDIES LIMITED.

*Ramanjit*

Ramanjit Kaur  
Assistant Manager  
Corporate Communication

## VENUS REMEDIES LIMITED

Corporate Office :  
51-52, Industrial Area, Phase-1,  
Panchkula (Hry.) 134113, India  
Regd. Office :  
SCO 857, Cabin No. 10, 2nd Floor, NAC,  
Manimajra, Chandigarh (U.T.) 160101, India  
Website : [www.venusremedies.com](http://www.venusremedies.com)  
[www.venusmedicineresearchcentre.com](http://www.venusmedicineresearchcentre.com)



Unit-I :  
51-52, Industrial Area, Phase-1, Panchkula (Hry.) 134113, India  
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566  
Unit-II :  
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),  
Bhatoli Kalan, Baddi (H.P.) 173203, India  
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272  
Unit-V :  
VENUS PHARMA GmbH  
AM Rohnhof 1.2 D-50240 Wesseling